二(2-氯-4-甲基-6-喹啉基)甲烷 | 500349-71-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 二(2-氯-4-甲基-6-喹啉基)甲烷
• 英文名称: 2-chloro-6-[(2-chloro-4-methylquinolin-6-yl)methyl]-4-methylquinoline
• 英文别名: bis-(2-chloro-4-methyl-[6]quinolyl)-methane；Bis-(2-chlor-4-methyl-[6]chinolyl)-methan；NSC 109451；Bis(2-chloro-4-methyl-6-quinolyl)methane
• CAS: 500349-71-3
• 化学式: C₂₁H₁₆Cl₂N₂
• 分子量: 367.277
• InChiKey: RVHRUJSUMLKIHE-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185 °C
• 沸点：
  548.6±45.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  吗啉 、 二(2-氯-4-甲基-6-喹啉基)甲烷 生成 4-[4-甲基-6-[(4-甲基-2-吗啉-4-基喹啉-6-基)甲基]喹啉-2-基]吗啉
  参考文献：
  名称：

  Diquinolylmethanes

  摘要：

  DOI：

  10.1021/ja01196a038
• 作为产物：
  描述：

  bis-(4-acetoacetylamino-phenyl)-methane 在 五氯化磷 、 硫酸 、 三氯氧磷 作用下， 生成 二(2-氯-4-甲基-6-喹啉基)甲烷
  参考文献：
  名称：

  Diquinolylmethanes

  摘要：

  DOI：

  10.1021/ja01196a038

文献信息

• COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：EP2897632A2

  公开（公告）日：2015-07-29
• Assays for identification of topoisomerase inhibitors
  申请人：Stivers T. James

  公开号：US20080020973A1

  公开（公告）日：2008-01-24

  The instant invention provides a continuous spectroscopic assay for DNA topoisomerase activity. The invention further provides topoisomerase inhibitors and pharmaceutical compositions for the treatment of topoisomerase associated diseases and disorders.
• USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：US20150337018A1

  公开（公告）日：2015-11-26

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.
• [EN] USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] UTILISATION DE COMPOSÉS QUI MODULENT SÉLECTIVEMENT LA LIBÉRATION ASTROCYTAIRE DE SUBSTANCES PAR LES HÉMICANAUX DE CONNEXINE ET DE PANNEXINE, SANS INFLUENCER LES JONCTIONS COMMUNICANTES, POUR LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES
  申请人：UNIV ANDRES BELLO

  公开号：WO2013179264A2

  公开（公告）日：2013-12-05

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.
• Diquinolylmethanes
  作者：C. E. Kaslow、R. A. Reck

  DOI：10.1021/ja01196a038

  日期：1947.4